Today In The Market | EnteroMedics (ETRM), Ariad Pharmaceuticals (ARIA), Baxalta (BXLT), Twitter (TWTR), Facebook (FB)

EnteroMedics Study Data Excites Investors EnteroMedics Inc (NASDAQ: ETRM) EnteroMedics is having a great day in the market today as investors are focused on the an analyses of the company’s ReCharge Study. The analyses demonstrated Excess Weight Loss of 34% and improvement in obesity-related risk factors associated with vBloc. While the data hit the media … Read more

Ariad Pharmaceuticals (ARIA) Stock: Are Investors Losing Acquisition Hopes?

Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) Ariad Pharmaceuticals is having a horrible day in the market today. This comes after a massive climb last week in which the stock gained more than 40% in a single day. The climb ARIA experienced last week was a result of an announcement of talks between the company and Baxalta … Read more

Stock Market News Today: Ariad Pharmaceuticals (ARIA), Baxalta (BXLT), Twitter (TWTR), Gilead Sciences (GILD), SunEdison (SUNE)

Ariad Pharmaceuticals Declines Baxalta Offer Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) | Baxalta Inc (NYSE: BXLT) One of the biggest conversations in the biotech space has been a discussion with regard to whether or not Baxalta will acquire Ariad Pharmaceuticals. The original offer on the table was $2 billion. However, Ariad Pharmaceuticals declined the offer – … Read more

Baxalta (BXLT) Acquisition Of Ariad (ARIA): The Deal Needs To Be Sweeter!

Baxalta Inc (NYSE: BXLT) | Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) One of the biggest pieces of news in biotech at the moment is Baxalta’s desire to acquire Ariad Pharmaceuticals. However a wrench may have been thrown into the idea. Yesterday, I reported that while we knew the acquisition talks were under way, we didn’t know … Read more

In The Market Today: Ariad Pharmacueticals (ARIA) | Baxalta (BXLT) | MannKind (MNKD) | The Medicines Company (MDCO) | Twitter (TWTR)

Ariad Pharmaceuticals: Is An Acquisition Coming? Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) | Baxalta Inc (NYSE: BXLT) On Friday, Bloomberg broke a story stating that Ariad Pharmaceuticals and Baxalta were in the midst of acquisition talks. The idea here is that Baxalta wants to purchase Ariad Pharmaceuticals to get hold of the work they’ve been doing … Read more

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

Abbott Laboratories (ABT) spun-off biopharmaceutical business AbbVie (ABBV) in 2013. Baxter International (BAX) must have been paying   attention. The company spun-off its own biopharmaceutical business this year. The new business is called Baxalta (BXLT). Baxalta has a market cap of $27 billion, while AbbVie has a market cap of $114 billion. Baxter and Abbott both … Read more

Undervalued Baxalta Shares Target of Acquisition by Shire Plc

Baxalta (BXLT) was recently spun-off from Baxter International (BAX) on July 1st, 2015. The company has 16,000 employees and around $6 billion in expected revenues. Baxalta is expected to have around $2.15 in earnings-per-share in its first full fiscal year. The company has traded around $32 a share since the spin-off. This translates to a … Read more

Baxalta: A Rare Undervalued Biopharmaceutical Company

Baxalta (BXLT) was created on July 1st 2015 when Baxter (BAX) spun-off its biopharmaceutical division. Baxalta may be new, but it is no start-up company.  Baxalta has estimated annual revenues of around $6 billion, and 16,000 employees. Around 50% of Baxalta’s sales come from the United States, with the other 50% from international markets. The … Read more